Daily MedNews
Printable Version   Email to a friend

Scientists ID New Proteins in Programmed Cell Death

THURSDAY, Aug. 21 -- U.S. researchers have identified 170 more proteins to add to the 91 already known to be associated with programmed cell death, or apoptosis.

They also uncovered new information about how these proteins may function. The findings may help in the development of new drug treatments for stroke and a number of diseases, the researchers said.

For this study, a team at the Scripps Research Institute in California used a new technique they named PROtein Topography and Migration Analysis Platform (PROTOMAP) to analyze proteolysis, the act of enzymes breaking down larger proteins into smaller components.

It's believed that more than 500 enzymes are involved in proteolysis, a critical driver of apoptosis and processes such as blood coagulation, infectious diseases and the onset of cancer.

Along with identifying the 170 new proteins involved in apoptosis, the researchers learned more about how these proteins function.

It had been believed that protein breakdown during proteolysis was a process of disassembling proteins for disposal, and that only a few of the breakdown products remained to serve specific functions.

But the Scripps team said it appears that most protein breakdown products actually serve new functions, and only a handful are fully degraded.

They said the new proteins identified in this study should be studied more closely, because some may prove good targets for drugs to treat conditions in which apoptosis goes awry, such as strokes, in which brain cells are killed prematurely.

The study was published in the Aug. 22 issue of the journal Cell.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about stroke.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
December 2, 2008
Audience: Hematological and Nephrological healthcare professionals, hospital risk managers [Posted 12/02/2008] FDA has received...
December 2, 2008
Audience: Oncologists, other healthcare professionals[UPDATE 12/02/2008] FDA issued Q&As for recently approved Medication...
November 26, 2008
Audience: Consumers, healthcare professionals [Posted 11/26/2008] Balanced Health Products, Inc. announced a recall of STARCAPS...
November 26, 2008
Audience: Consumers, healthcare professionals [Posted 11/26/2008] Fashion Sanctuary announced a recall of Zhen De Shou Fat Loss...
More...
Latest Drug Information Updates

Promacta
Promacta (eltrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.

Banzel
Banzel (rufinamide) is a triazole derivative antiepileptic drug for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

More...